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The objectives of this study were to determine the structural
characteristics of perfluoroalkyl acids (PFAAs) that confer estro-
gen-like activity in vivo using juvenile rainbow trout (Oncorhynchus
mykiss) as an animal model and to determine whether these
chemicals interact directly with the estrogen receptor (ER) using
in vitro and in silico species comparison approaches. Perfluor-
ooctanoic (PFOA), perfluorononanoic (PFNA), perfluorodecanoic
(PFDA), and perfluoroundecanoic (PFUnDA) acids were all potent
inducers of the estrogen-responsive biomarker protein vitellogenin
(Vtg) in vivo, although at fairly high dietary exposures. A structure-
activity relationship for PFAAs was observed, where eight to ten
fluorinated carbons and a carboxylic acid end group were optimal
for maximal Vtg induction. These in vivo findings were corrobo-
rated by in vitro mechanistic assays for trout and human ER. All
PFAAs tested weakly bound to trout liver ER with half maximal
inhibitory concentration (IC50) values of 15.2–289mM. Additionally,
PFOA, PFNA, PFDA, PFUnDA, and perlfuorooctane sulfonate
(PFOS) significantly enhanced human ERa-dependent transcrip-
tional activation at concentrations ranging from 10–1000nM.
Finally, we employed an in silico computational model based upon
the crystal structure for the human ERa ligand-binding domain
complexed with E2 to structurally investigate binding of these
putative ligands to human, mouse, and trout ERa. PFOA, PFNA,
PFDA, and PFOS all efficiently docked with ERa from different
species and formed a hydrogen bond at residue Arg394/398/407
(human/mouse/trout) in a manner similar to the environmental
estrogens bisphenol A and nonylphenol. Overall, these data support
the contention that several PFAAs are weak environmental
xenoestrogens of potential concern.
Key Words: perfluoroalkyl acid; estrogen; perfluorooctanoic
acid; perfluorooctane sulfonate; vitellogenin; molecular docking.
The widespread industrial and commercial use of
polyfluorinated chemicals (PFCs) as surfactants and surface
protectors for paper and textile coatings, polishes, food
packaging, and fire-retardant foams has led to the pervasive
presence of these chemicals in the environment, wildlife, and
humans (see reviews by Calafat et al., 2007; Houde et al.,
2006). The general structure of PFCs resembles that of fatty
acids in that each compound has a hydrophobic polyfluorinated
carbon tail of varying length and a functional end group, which
provides the basis for classification (Fig. 1). Perfluoroalkyl
acids (PFAAs) and fluorotelomers comprise the two major
structural groups of PFCs. Human blood levels of
perfluorooctanoic acid (PFOA) and perlfuorooctane sulfonate
(PFOS), the two most commonly studied PFCs, are about 4
and 20 ppb, respectively, although national survey data suggest
that these levels have decreased in recent years (Calafat et al.,
2007). Levels of PFOS and PFOA in wildlife tend to be higher,
in the range of tens to thousands ppb (Kannan et al., 2002).
Other PFCs commonly detected in biological samples
include perfluorononanoic acid (PFNA), perfluorodecanoic
acid (PFDA), perfluoroundecanoic acid (PFUnDA), and
perfluorododecanoic acid (PFDoDA).
The toxicology and toxicokinetics of PFOA, as an example
PFC, have been thoroughly reviewed by Kennedy et al. (2004).
PFOA does not accumulate in fatty tissues because of its dual
lipophobic and hydrophobic chemical properties but instead
binds to blood proteins and is distributed primarily to liver,
plasma, and kidney. The measured biological half-life of PFOA
varies among species ranging from hours in female rat to days
in dogs or rainbow trout (Hanhijarvi et al., 1988; Martin et al.,
2003). The estimated half-life of PFOA in humans is nearly 4
years, pointing to a lower capacity for elimination of the
compound compared with other species (Olsen et al., 2007).
Finally, PFOA is not metabolized or defluorinated in vivo,
although some fluorotelomer compounds may be metabolized
to PFAAs in rodents (Martin et al., 2005; Nabb et al., 2007).
PFOA and other PFCs are members of a large group
of chemicals called peroxisome proliferators (PPs), which
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increase the abundance of hepatic peroxisomes and induce
peroxisomal and mitochondrial enzymes involved with
b-oxidation, cytochrome P450 fatty acid x-oxidation, and
cholesterol homeostasis (reviewed in Bosgra et al., 2005)
via ligand-dependent activation of the hepatic PP-activated
receptor a (PPARa) (Holden and Tugwood, 1999). Prolonged
exposure to PPs, including PFOA, can result in
hepatocarcinogenesis (Abdellatif et al., 1991), although
marked species differences in susceptibility to PPs have been
observed. Whereas rodents are highly susceptible, humans
and nonhuman primates are insensitive or nonresponsive
(Lai, 2004), possibly due low expression of PPARa in liver
(Palmer et al., 1998). Recent evidence points to
PPARa-independent mechanisms of action for increased
risk of liver cancer by PPs, suggesting that the assumption
that PPARa agonists pose little risk for human
hepatocarcinogenesis may be unsound (reviewed in Guyton
et al., 2009). For example, chronic exposure to the
FIG. 1. Structures for known xenoestrogens (A), select PFAAs (B), and fluorotelomer (C) compounds are shown.
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environmental PPARa agonist di(2-ethylhexyl) phthalate
increased liver cancer incidence in PPARa knockout mice
(Ito et al., 2007).
Estrogens have long been known to be associated with cancer
in estrogen-responsive tissues including the breast, ovary, and
uterus as complete carcinogens, promoters, or possible chemo-
protective agents (Cavalieri et al., 2000; Eliassen and Hankin-
son, 2008; Ho, 2003; Persson, 2000). Moreover, estrogens also
influence carcinogenesis in other tissues not usually considered
to be estrogen responsive. Experimental studies investigating
hepatic cancer in mammalian animal models have implicated
estrogens as tumor promoters and in some cases complete
carcinogens (reviewed in De Maria et al., 2002; Yager et al.,
1991), although the higher rate of hepatic cancer in males
suggests the potential for a protective role of estrogens against
liver cancer (Villa, 2008; Yeh and Chen, 2010). Several studies
in our laboratory using the rainbow trout cancer model have also
demonstrated that estrogen exposure promotes hepatocellular
carcinogenesis in rainbow trout (Nu´n˜ez et al., 1989; Orner et al.,
1995).
Previously, we reported that PFOA may act via an alternative
mechanism of action, not involving peroxisome proliferation, to
increase risk of liver cancer in rainbow trout, an animal model
that mimics human insensitivity to PPs (Tilton et al., 2008).
Dietary exposure to PFOA significantly increased expression of
the sensitive estrogen biomarker protein vitellogenin (Vtg) and
induced an overall hepatic gene expression profile highly similar
to that of 17b-estradiol (E2). We concluded that the cancer-
enhancing effects of PFOA in trout were due to novel
mechanisms related to estrogen signaling rather than the typical
PP response observed for this chemical in rodent models (Tilton
et al., 2008). Studies in other model organisms support the
concept that certain PFCs may have estrogen-like activity. Liu
et al. (2007) reported that PFOA, PFOS, and 6:2 fluorotelomer
alcohol (6:2FtOH) increased Vtg expression in cultured tilapia
hepatocytes, and Wei et al. (2007) showed that PFOA increased
Vtg expression and caused disruption of gonad development in
rare minnows (Gobiocypris rarus). Evidence for estrogen-like
activity of some fluorotelomers has also been shown in vitro
(Ishibashi et al., 2007; Maras et al., 2006).
Though several laboratories have shown estrogenic effects of
certain PFCs in vitro and in vivo, it is yet unknown whether any
of these chemicals interact directly with the estrogen receptor
(ER). This receptor is generally considered to be quite pro-
miscuous because dozens of structurally diverse exogenous
chemicals, including phytochemicals, hydroxylated polychlori-
nated biphenyls, pesticides, and other industrial compounds, have
been shown to bind to the receptor with varying degrees of
affinity (Blair et al., 2000; Matthews et al., 2000; Olsen et al.,
2005). The optimal chemical structure for ligand binding to the
ER is a four-ring arrangement with opposing hydroxyl end
groups, although long-chain compounds, such as nonylphenol,
have been shown to effectively bind to the protein as well
(Matthews et al., 2000; Sivanesan et al., 2005).
In this present study, we determined the relationship between
PFC structure and estrogen-like activity using the Vtg
induction bioassay in rainbow trout to test the hypotheses that
PFCs structurally similar to PFOA are estrogenic and that the
Vtg response depends largely on chemical structure. We also
assessed the interaction of PFAAs with the ER using direct
steroid receptor-binding assays for trout liver ER and a gene
reporter assay for human ERa. Finally, we employed
computational modeling to determine the molecular interaction
of these compounds with the ligand-binding domains (LBDs)
of human, mouse, and trout ERa proteins.
MATERIALS AND METHODS
Chemicals
A complete list of PFCs investigated in this study, including their
common names, abbreviations, and registry numbers for reference, is provided
in Supplementary table 1. Perfluoroalkyl carboxylic acid and sulfonate
compounds were all purchased from Sigma-Aldrich (St Louis, MO), except
for perfluorodecane sulfonate (PFDS), which was graciously donated by Dr
Jennifer Field (Oregon State University). Fluorotelomer alcohol and acrylate
compounds were obtained from SynQuest Labs (Alachua, FL). E2, genistein
(GEN), diethylstilbestrol (DES), ethynylestradiol (EE2), indole-3-carbinol
(I3C), 3,3#-diindolylmethane (DIM), 4-nonylphenol (NP), and all other
reagents were purchased from Sigma-Aldrich or other general laboratory
suppliers and were of the highest purity available. [2,4,6,7-3H]-17b-estradiol
(70 Ci/mmol) was purchased from Perkin Elmer (Waltham, MA).
Animal Care
Mt Shasta strain rainbow trout were hatched and reared at the Sinnhuber
Aquatic Research Laboratory (SARL) at Oregon State University in Corvallis,
OR. Fish were maintained in flow-through 375-l tanks at 12C with activated
carbon water filtration on a 12:12 h light:dark cycle. Two weeks prior to
experimental treatments, fish were fed a maintenance ration (2% of body
weight [bw]) of Oregon Test Diet (OTD), a semipurified casein-based diet with
menhaden oil as the lipid. All experimental diets described below were
administered for 14 days, and feeding occurred 5 days per week. On day 15,
trout were euthanized with an overdose (250 ppm) of tricane methanesulfonate
and necropsied. Body and liver weights were recorded to calculate the liver
somatic index (LSI ¼ liver weight/bw 3 100), and blood samples from each
donor animal were obtained. The plasma fraction of each blood sample was
obtained by centrifugation at 850 3 g and then frozen at 80C. All
procedures for treatment, handling, maintenance, and euthanasia of trout used
in this study were approved by the Oregon State University Institutional
Animal Care and Use Committee.
In Vivo Experimental Procedures
Experiment 1—subchronic dietary exposure to PFCs. A variety of
structurally diverse PFCs were chosen to test in vivo in juvenile rainbow trout,
including perfluoroalkyl carboxylic acids with 6–14 fluorinated carbons, two
perfluoroalkyl sulfonates, and three fluorotelomers. Eleven-month-old juvenile
trout (initial bw approximately 70 g) were distributed to holding tanks 1 week
prior to the start of feeding experimental diets. Test chemicals were dissolved in
dimethylsulfoxide (DMSO) vehicle ( 0.5 ppm) and added directly to the oil
portion of the custom trout OTD diet. PFCs were administered at a diet
concentration of 250 ppm calculated with respect to diet wet weight
(approximately 5 mg/kg bw/day) to six fish per treatment group. Additionally,
PFOA, PFNA, PFDA, and PFUnDA were selected for testing in a simple
mixture study. Two additional dietary groups at 5 and 50 ppm (0.1 and 1 mg/kg
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bw/day) were added to the experiment for these four compounds so that three
concentrations in total were tested for each individual chemical (5, 50, and 250
ppm). Mixture treatments were prepared by combining equal mass amounts of
each test compound at each concentration level. Thus, mixture A consisted of 5
ppm each PFOA, PFNA, PFDA, and PFUnDA for a total perfluoroalkyl
carboxylic acid concentration of 20 ppm. Similarly, mixture B was made by
combining 50 ppm each chemical for a total diet concentration of 200 ppm;
finally, mixture C was prepared by combining 250 ppm each compound for
total concentration of 1000 ppm. The control group (N ¼ 24, six fish in four
replicate tanks) was fed OTD diet with no modifications; the vehicle control
group was fed diet with 0.5 ppm DMSO (N ¼ 6), and 5 ppm E2 was included
as a positive control (N¼ 12, six fish in two replicate tanks). The additional fish
were included in the E2 positive and the control groups to account for multiple
sampling days.
Experiment 2—dose-dependent induction of Vtg by PFOA and
PFDA. The goal of this experiment was to determine the dose-dependent
impact of dietary exposure to PFOA and PFDA on trout blood Vtg levels.
PFOA and PFDA were selected as test compounds for this experiment because
of their common detection in wildlife and humans and the observed robust
induction of Vtg by both chemicals in experiment 1. Each experimental group
consisted of a single tank of 5-month-old individual juvenile trout with an
initial approximate bw of 30 g. The control group (N ¼ 16) was fed OTD
diet with no modifications, and 5 ppm E2 diet was used as a positive control
(N ¼ 16). Eight trout per treatment group were fed experimental diets
containing either PFOA or PFDA at concentrations of 0.026, 0.128, 0.64, 3.2,
16, 80, 400, or 2000 ppm calculated with respect to diet wet weight (range of
0.52 lg/kg bw/day up to 40 mg/kg bw/day). In this study, the test compounds
were added directly to the oil portion of the diet, which was gently heated
(< 50C) to aid in chemical dissolution.
Vtg ELISA
Blood plasma Vtg was measured following an ELISA method previously
described (Shilling and Williams, 2000) with modifications as outlined by
Benninghoff and Williams (2008). For this study, the interassay coefficient of
variance for the Vtg ELISA was 7.1% with an assay detection limit of 6.25
ng/ml.
Measurement of Palmitoyl Coenzyme A Oxidation and Catalase Activity
Peroxisomal fractions of liver tissues were prepared by differential
centrifugation, and catalase activity was assessed following the methods
described by Orner et al. (1995). Beta-oxidation of palmitoyl coenzyme A
(CoA) was measured using a spectrophotometric assay as previously described
(Mitchell et al., 1985).
PFOA and PFDA Blood Content by Liquid Chromatography-Tandem Mass
Spectrometry
Complete methods for the determination of PFOA and PFDA content in
trout blood plasma samples are provided in the Supplementary materials
including details on the instrumentation, quality control, sample preparation,
liquid chromatography-tandem mass spectrometry/(LC-MS/MS) conditions,
and quantitation. Briefly, measurement of PFOA and PFDA was performed at
the 3M Medical Department, and this laboratory was blinded to any
information on the effects of PFOA or PFDA on Vtg expression in trout. A
Shimadzu High Performance Liquid Chromatography (HPLC) system free of
contaminating polytetrafluoroethylene-based materials was used in conjunction
with an API 5000 triple stage quadrupole mass spectrometer. Samples were
prepared by solid phase extraction with Waters Oasis HLB cartridges. PFOA
and PFDA standard materials were the free acid linear isoforms, and internal
dual 13C-labeled PFOA and PFDA standards were used for quantitation.
Trout Liver ER-Binding Studies with PFCs
Preparation of trout liver cytosol. Juvenile trout were fed control OTD
diet (N ¼ 24) or supplemented with 5 ppm E2 (N ¼ 24). Livers were pooled in
groups of six, homogenized in two volumes of ice-cold TEMS buffer (10mM
Tris-HCl, 1mM EDTA, 12mM monothioglycerol, 20mM sodium molybdate,
10% vol/vol glycerol, and 0.1mM phenylmethanesulfonylfluoride), and
centrifuged at 100,000 3 g for 15 min at 4C. Two volumes of ice-cold
TEMS buffer containing 5% wt/vol activated charcoal and 0.5% wt/vol dextran
were added to the supernatant, which was mixed, incubated on ice for 15 min,
and then centrifuged at 100,000 3 g for 90 min at 4C. The upper lipid layer
was removed, and the remaining supernatant was spun at 100,000 3 g for an
additional 30 min. Again, the lipid layer was aspirated, and the resulting
supernatant (the cytosol fraction) was collected, aliquoted, and stored at 80C
until use.
ER saturation binding assays. Saturation analyses were performed by
incubating 200ll of charcoal-stripped cytosol (5 mg protein per milliliter) with
25 ll of [3H]-E2 (final concentration 0.1–25nM) in TEMS buffer for 24 h at
12C. ER saturation binding assays were performed with separate cytosol
preparations from control and E2-exposed trout. Nonspecific binding was
determined by incubating cytosol with [3H]-E2 and DES (10–2.5lM) and was
defined as the fraction of total binding displaced by 100-fold excess DES. Free
steroid was separated from bound by incubation with 500ll of TEMS with
2.5% wt/vol activated charcoal and 0.25% wt/vol dextran for 30 min on ice
followed by centrifugation at 3000 3 g for 10 min. Bound [3H]-E2 was
measured in the supernatant by liquid scintillation counting (Beckman
Instruments Inc., Fullerton, CA).
ER competitive binding assays. Competitive binding assays were
performed by incubating 200ll charcoal-stripped cytosol (5 mg protein per
milliliter, 200 microliters per assay tube) extracted from livers of E2-exposed
trout, 25ll of [3H]-E2 in TEMS buffer at a final concentration of 4nM (near
saturating concentration), and 25ll of cold competitor for 24 h at 12C.
Competitor stock solutions were prepared in TEMS buffer with DMSO
(5% final assay concentration). Bound [3H]-E2 was measured as described
above. Competitors were assayed according to the anticipated affinity of the
putative ligand (1pM–10lM for strong binders and 10lM–100mM for weak
binders). Maximum nonspecific binding was determined using 100lM E2 and
was subtracted from all total count values to determine specific binding.
Human ERa Gene Reporter Assay
Human embryonic kidney (HEK-293T) cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) with L-glutamine (Mediatech, Manassas,
VA) supplemented with 10% fetal bovine serum (FBS, Tissue Culture
Biologicals, Seal Beach, CA) and 10,000 U/ml penicillin-streptomycin
(Mediatech) in a humidified, 5% CO2 atmosphere. HEK-293T cells were
seeded in 96-well microplates at 10,000 cells per well in 100 ll phenol red-free
DMEM with 10% charcoal-stripped FBS. Cells were cotransfected 24 h after
seeding with the following: 70 ng of the XTEL luciferase reporter plasmid
containing a consensus estrogen-responsive element (ERE) sequence from the
Xenopus Vtg promoter (graciously donated by Dr Michael Garabedian, New
York University School of Medicine) and 10 ng of the human ERa expression
vector (Kolluri et al., 2003), an independent b-galactosidase reporter driven by
a cytomegalovirus (CMV) promoter and pcDNA for DNA input normalization
(Invitrogen, Carlsbad, CA). Each well received 0.2 ll of PLUS reagent with 0.2
ll of lipofectamine (Invitrogen). Twenty-four hours after transfection, cells
were treated with E2, PFOA, PFNA, PFDA, PFUnDA, PFOS, or 8:2FtOH at
concentrations ranging from 1 to 1000nM for 24 h. Cells were then lysed and
measured for reporter gene activity as previously described (Bisson et al.,
2009). Raw luminescence data were normalized by b-galactosidase activity to
account for any variability in transfection efficiency; then, values for ERa gene
reporter activity were expressed as fold induction with respect to vehicle-only
cells.
In Silico Modeling of PFC Interaction with Human, Mouse, and Trout ERa
Proteins
Molecular modeling. The 3D coordinates of the human ERa (hERa) LBD
complexed with the natural agonist E2 were taken from the crystal structures
available in the Protein Data Bank (accession 1ERE) (Brzozowski et al., 1997).
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Following protein sequence alignment of the LBD regions for the mouse Esr1
and trout era1 proteins (UniProt accessions P19785 and P16058, respectively)
using ClustalW2 (EMBL-EBI), homology models for mouse ERa (mERa) and
rainbow trout ERa (rtERa) proteins were built based upon 1ERE as the 3D-
template with Molsoft ICM v3.5-1p (Molsoft, L.L.C., La Jolla, CA). Rainbow
trout have two isoforms of ERa, era1 and era2 (Nagler et al., 2007); because
era1 is the ERa isoform abundantly expressed in the liver, we selected this
sequence for constructing the homology model. The percent identities of the
mouse Esr1 and trout era1 protein sequences to that of the human ERa were 89
and 46%, respectively. All models were energetically refined in the internal
coordinate space with Molsoft ICM v3.5-1p (Cardozo et al., 1995).
Molecular docking. The receptor is represented by five types of
interaction potentials: (1) van der Waals potential for a hydrogen atom probe,
(2) van der Waals potential for a heavy-atom probe (generic carbon of 1.7 A˚
radius), (3) optimized electrostatic term, (4) hydrophobic terms, and (5)
loan-pair–based potential, which reflects directional preferences in hydrogen
bonding. The energy terms are based on the Merck Molecular Force Field to
account for solvation free energy and entropic contribution (Totrov and
Abagyan, 2001). Modified intermolecular terms such as soft van der Waals
and hydrogen bonding, as well as a hydrophobic term, are added.
Conformational sampling is based on the biased probability Monte Carlo
procedure, which randomly selects a conformation in the internal coordinate
space and then makes a step to a new random position independent of the
previous one, but according to a predefined continuous probability distribution.
It has also been shown that after each random step, full local minimization
greatly improves the efficiency of the procedure. In the ICM-virtual ligand
screening (VLS) procedure (Molsoft ICM v3.5-1p), the ligand scoring is
optimized to obtain maximal separation between the binders and nonbinders.
Each compound is assigned a score according to its fit within the receptor; this
ICM score accounts for continuum and discreet electrostatics, hydrophobicity,
and entropy parameters (Abagyan et al., 1994; Totrov and Abagyan, 1997,
2001).
Data Analysis
For in vivo experiments, an individual animal consisted of a single
biological replicate, and the sample size is indicated in each figure legend or
table. For most experiments, a one-way ANOVA test with Dunnett’s multiple
comparisons post hoc test was employed for statistical analyses of the data
(Prism 5, GraphPad Software, LaJolla, CA). For analyses of Vtg data, all values
were log10 transformed to equalize variance prior to statistical analyses.
A significant effect of an experimental treatment was inferred when p < 0.05.
RESULTS
Experiment 1—Subchronic Dietary Exposure to PFCs
The objective of this experiment was to determine the impact
of subchronic dietary exposure to structurally diverse PFCs,
including PFAAs and fluorotelomers, on Vtg expression and to
determine whether a structure-activity relationship was evident.
As expected, short-term dietary exposure to 5 ppm E2 caused
FIG. 2. Effects of subchronic dietary exposure to select PFAAs and
fluorotelomers on plasma Vtg concentration. (A) Mean blood plasma Vtg
values are shown on a logarithmic scale þ SEM (N ¼ 18 for control, N ¼ 12
for E2, and N ¼ 6 for all other treatments). The diet concentration was 250 ppm
(approximately 5 mg/kg bw/day) for all perfluoroalkyl compounds and 5 ppm
for E2, the positive control. (B) For individual chemical treatments, fish were
fed diets containing 0, 5, 50, or 250 ppm of PFOA, PFNA, PFDA, and
PFUnDA. Mean blood plasma Vtg values are shown on a logarithmic scale þ
SEM (N ¼ 18 for control and N ¼ 6 for all other treatments). (C) The
mixture treatments were prepared by adding equal amounts of each constituent
chemical to achieve total concentrations of 20, 200, and 1000 ppm as described
in the ‘‘Materials and Methods’’ section. Closed squares represent the
measured mean blood plasma Vtg values ± SEM for the mixture treatments
(N ¼ 6). Open circles represent the predicted level of Vtg response at each
concentration calculated using a simple CA model. *p < 0.05, **p < 0.01, and
***p < 0.001 compared with control (for B, within a diet group) as determined
by one-way ANOVA with Dunnett’s multiple comparisons post hoc test.
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a large > 10,000-fold increase in plasma Vtg levels (Fig. 2A)
compared with control fish. Exposure to small perfluoroalkyl
carboxylic acids with six or seven fluorinated carbons did not
significantly alter plasma Vtg levels, whereas medium and
long-chain perfluoroalkyl carboxylic acids with 8–14
fluorinated carbons significantly induced Vtg expression by
7- to 190-fold. PFOA, PFNA, PFDA, and PFUnDA were the
most potent inducers of Vtg, although the level of response
was substantially lower than that of E2. The perfluoroalkyl
sulfonates PFOS and PFDS induced a minor three- to
fourfold increase in blood Vtg levels. Overall, the
fluorotelomers tested had little effect on plasma Vtg levels,
with only one compound, 6:2FtOH, causing a modest
eightfold increase.
The perfluoroalkyl carboxylic acids PFOA, PFNA, PFDA,
PFUnDA, and PFDoDA all caused a significant increase in
relative liver size, though the response to PFDoDA was
unexpectedly high (Supplementary table 2). Although only the
fluorotelomer compound 6:2FtOH was effective in increasing
Vtg expression, 8:2FtOH and 8:2FtOAcr caused a significant
increase in relative liver weight. Overall, for this dietary
screening study, there was a significant correlation between
Vtg response and LSI with a Spearman’s correlation r value of
0.62 (p ¼ 0.022).
Four perfluoroalkyl carboxylic acids, PFOA, PFNA, PFDA,
and PFUnDA, were tested at diet concentrations ranging
from 5 to 250 ppm and also in a quaternary mixture
(20–1000 ppm). For each individual chemical, a significant
concentration-dependent induction of Vtg expression was
observed (p < 0.0001 by one-way ANOVA) (Fig. 2B).
Bonferroni post hoc tests revealed that PFOA, PFNA, and
PFDA exposures at 50 and 250 ppm caused significant
increases in plasma Vtg levels, whereas the response to
PFUnDA was only significant at 250 ppm. To calculate the
predicted response to the PFOA/PFNA/PFDA/PFUnDA
mixture, a simple concentration addition (CA) model was
employed, where the response for each individual
compound was summed at each concentration level (Fig.
2C). For example, at the middle exposure, Vtg levels of
7726 ng/ml for PFOA þ 4083 ng/ml for PFNA þ 2008
ng/ml for PFNA þ 1410 ng/ml for PFUnDA yielded a CA
prediction model value of 15,227 ng/ml for the quaternary
mixture. At the lowest concentration level, the observed
response to the carboxylic acid mixture was about half of
that predicted by the CA model. Alternatively, at the
medium and higher diet concentrations, the mixture
treatment induced Vtg at levels 1.8- and 2.2-fold higher,
respectively, than the predicted response. As these in vivo
data sets were limited in the number of exposure
levels examined, a nonlinear regression analysis for curve
comparisons was not performed.
Finally, palmitoyl CoA oxidation and catalase activity
were measured as markers of peroxisome proliferation; a subset
of the compounds tested in experiment 1 were selected for
enzyme activity analyses, including those chemicals that
strongly induced Vtg as well as representative compounds
from each structural group. None of the test agents significantly
increased peroxisomal palmitoyl CoA oxidation or catalase
activity in trout liver, whereas 6:2FtOH and 8:2FtOH
apparently decreased catalase activity (Supplementary fig. 1).
Experiment 2—Dose-Dependent Induction of Vtg by PFOA
and PFDA
PFOA and PFDA levels in trout blood. A strong linear
dose-response relationship between the concentration of
PFOA or PFDA administered in the diet and the amount of
compound measured in trout blood plasma was observed
(Fig. 3A) with linear regression R2 values of 0.86 and 0.95,
respectively. However, at the very highest concentration of
PFDA tested (2000 ppm), the measured blood concentration
of PFDA was slightly lower than indicated by the linear model,
suggesting that this or higher dietary concentrations may exceed
the limits for PFDA absorption in trout. The lowest dietary
concentration tested (25.6 ppb or 0.5 lg/kg bw/day) resulted
in blood levels of these compounds in the low nanomolar
range: 17.3 ± 1.82nM for PFOA and 85.8 ± 4.79nM for
PFDA, whereas the highest dietary concentrations (2000 ppm
or 40 mg/kg bw/day) resulted in blood levels of 508 ± 35lM for
PFOA and 1.36 ± 0.11mM PFDA.
Dose-dependent induction of Vtg by PFOA and
PFDA. PFOA and PFDA caused a significant dose-dependent
induction of Vtg expression in trout with a maximal response-
similar to that of E2 (p < 0.0001 by separate one-way ANOVA
for PFOA and PFDA) (Fig. 3B). Bonferroni post hoc tests
indicated that the lowest observed effect level (LOEL) for
PFOA exposure was at the 80 ppm diet (1.6 mg/kg bw/day)
level or 35.4lM PFOA in blood plasma (Table 1).
Alternatively, the LOEL for PFDA was much lower at 0.64
ppm (12.8 lg/kg bw/day) or 2.0lM PFDA in blood plasma.
Although PFOA did not induce a significant increase in Vtg
below the relatively high diet concentration of 80 ppm, the
dose-response curve for this compound was substantially left
shifted compared with that of PFDA, resulting in an
substantially lower estimated effective concentration at 50%
response (EC50) value, 182lM for PFOA compared with
360lM for PFDA. However, this lower EC50 value did not
correlate with a lower PFOA dietary exposure, likely a result of
the higher half-life and lower elimination rate of PFDA in trout
compared with PFOA (Martin et al., 2003). The corresponding
amount of dietary PFOA to achieve the EC50 value of 182lM
is 458 ppm, whereas a dietary PFDA concentration of 214 ppm
corresponds with its EC50 value of 360lM (Table 1). A dose-
dependent effect of increasing diet concentrations of PFOA and
PFDA on relative liver size was less evident in this experiment,
as only the highest diet concentrations significantly increased
LSI values, 2000 ppm for PFOA and > 400 ppm for PFDA
(Supplementary table 3).
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Trout Hepatic ER-Binding Studies
Radiolabeled E2 binding in liver cytosol extract from
E2-exposed rainbow trout showed a single class of high-
affinity binding sites that saturated at 5–10nM [3H]-E2 with an
equilibrium dissociation constant (Kd) value of 4.4 ± 0.7nM
and measured binding capacity (Bmax) value of 152 ± 4.9pM
(38 pmol/g protein) (Supplementary fig. 2). At the near
saturating concentration of 4nM [3H]-E2, a larger fraction of
total binding was specific binding (about 75%) for the
E2-exposed liver cytosol compared with only about 50% for
the control cytosol. Therefore, all competitive binding
experiments were conducted using the cytosol protein from
E2-exposed fish because of the greater dynamic range in which
to perform these assays.
In the radioligand competitive binding assays, the natural
hormone E2 bounds to the trout hepatic ER with an IC50 value
of 13.9nM (Fig. 4A, Table 2). The synthetic estrogen DES was
also a strong binder with a relative binding affinity (RBA)
value nearly twice that of E2, whereas EE2 binding was about
fivefold weaker. The dietary phytoestrogen GEN had moderate
binding affinity for the trout liver ER, with an RBA value of
about 1%. Though NP, DIM, and I3C all effectively displaced
[3H]-E2 from the ER, these compounds were classified as
weak-affinity ligands with IC50 values in the high micromolar
range and RBA values well below 0.01%.
An apparent relationship between the PFAA carbon chain
length and the strength of binding to the trout ER was
evident (Fig. 4, Table 2). The shortest (perfluoropentanoic acid)
and longest (PFDoDa, PFTrDA, and perfluorotetradecanoic
acid) compounds did not completely displace E2 from the ER.
Compounds of medium size (7–11 fluorinated carbons),
including perfluorohexanoic acid (PFHpA), PFOA, PFNA,
PFDA, and PFUnDA, had the highest affinities of the
carboxylic acids for the ER and completely displaced E2
from the receptor. Because the calculated RBA values for
these compounds were more than 10,000-fold lower than that
of E2, they were classified as weak or very weak binders.
PFDA had the highest affinity of the carboxylic acids tested for
the trout liver ER with IC50 and RBA values comparable to
that of the weak environmental estrogen NP. PFOS and PFDS
were also weak ligands for the trout liver ER, with RBA
values comparable to that of the similarly sized carboxylic
acid PFDA. In contrast, none of the fluorotelomers tested
displaced E2 from the receptor and were classified as
nonbinders in this study (Fig. 4F).
Human ERa Gene Reporter Assay
For all test compounds evaluated, the presence of the
hERa-expressing plasmid was required to increase gene
reporter activity (Fig. 5), although the assay had
FIG. 3. Dose-dependent effects of subchronic dietary exposure to PFOA
and PFDA on chemical concentrations in blood plasma and Vtg expression. (A)
Blood plasma concentrations of PFOA and PFDA following 2-week exposure to
a broad range of diet concentrations (0.0256–2000 ppm) are shown (N ¼ 8) in
a log-log plot. Results of linear regression analyses of nontransformed data are
represented by the solid lines, whereas the 95% confidence intervals are
represented by the dashed lines. (B) Mean blood plasma Vtg values are shown ±
SEM (N ¼ 8) for PFOA- and PFDA-exposed fish plotted according to the
measured blood concentrations of PFOA and PFDA, respectively. *p < 0.05 and
**p < 0.01 compared with the 0 ppm treatment group (CON) as determined by
one-way ANOVA with Dunnett’s multiple comparisons post hoc test.
TABLE 1
Dose-Response Curve Parameters for PFOA and PFDA
Induction of Vtg
PFOA PFDA
Parameter
Diet
(ppm)
Blood level
(lM)
Diet
(ppm)
Blood level
(lM)
LOEL 80 35.4 0.64 2.00
NOEL 16 7.83 0.128 0.48
EC50 458 182 214 360
EC10 141 60.1 118 212
Note. Experimentally determined values (diet concentrations) are shown in
bold for the LOEL and NOEL estimates, whereas the corresponding blood
levels were extrapolated from the standard curve shown in Figure 3A (diet
concentration vs. blood level). Experimentally calculated values (blood levels)
are shown in bold for EC50 and EC10 estimates, whereas the corresponding
dietary exposure level was extrapolated from the dose-response curve shown in
Figure 3B (Vtg induction vs. blood level). NOEL, no observed effect level;
EC10, effective concentration at 10% response.
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a somewhat limited dynamic range because of fairly high basal
activity of the gene reporter under the culture conditions
described above. (For this reason, EC50 and relative activity
values were not calculated for this assay.) Treatment of cells
with 1–1000nM E2 caused a significant, concentration-de-
pendent induction of hERa gene reporter activity, with
a maximal response of nearly threefold observed. PFOA,
PFNA, and PFDA significantly induced gene reporter activity
up to 2.5-fold at concentrations of 100–1000nM. PFOS
appeared to be the most effective of the PFAAs tested, with
significant induction of gene reporter activity observed at 1nM.
Alternatively, PFUnDA and 8:2FtOH did not significantly alter
gene reporter activity.
Molecular Docking Studies with hERa, mERa, and rtERa1
For this comparative molecular docking study, we included
human and trout ERa proteins as well as the mouse ERa, as
most of the toxicological assessments for this compound
class have been performed in mouse models. The LBD
regions of the human, mouse, and trout ERa proteins are
highly homologous, with perfect identity at amino acid sites
previously recognized as key for hydrogen bonding with
E2 (Supplementary fig. 3) (Brzozowski et al., 1997;
Marchand-Geneste et al., 2006). The molecular models for
human, mouse, and trout ERa proteins were constructed using
the experimentally resolved crystal structure available for
hERa and were energetically minimized in the internal
FIG. 4. Binding of known xenoestrogens and various PFCs to the trout hepatic ER. Competition assays were performed with 1 mg cytosolic protein in the
presence of 4nM [3H]-estradiol and increasing concentrations of test ligands, including known xenoestrogens (A), perfluoroalkyl carboxylic acids of increasing
carbon chain length (B–D), perfluoroalkyl sulfonic acids (E), and fluorotelomers (F). Symbols represent mean ± SEM specific binding for each test chemical.
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coordinate space as described in ‘‘Materials and Methods’’
section (Supplementary fig. 4). The root-mean-square deviation
(RMSD) values for superimposition of the mERa and rtERa1
homology models with the 3D crystal structure of hERa were
0.087 and 0.078 A˚, respectively (SuperImpose Algorithm,
ICM-Browser, Molsoft).
The natural ligand E2 docked within a 4-A˚ sphere around
its 3D position in the crystal structure with favorable ICM
scores of 38.68 (human), 37.75 (mouse), and 36.34
(trout) and a very low all atoms RMSD (< 0.151 A˚ for all three
models) when compared with the crystallographic orientation.
The hydrogen bond interactions observed in the crystal
structure between the phenolic hydroxyl group of the A-ring
and the hydroxyl group of the D-ring of the natural ligand and
the side chains of residues Glu353/357/366 (hERa/mERa/
rtERa1) of helix 2, Arg394/398/407 of helix 3, and His524/
528/537 of helix 8 were confirmed (Fig. 6). Sites of
hydrophobic interactions with the natural ligand were similar
to those previously identified (Marchand-Geneste et al., 2006).
To explain the effects observed in vitro (radioligand-binding
assay, cell-based assay) through ERa activation, PFHpA,
PFOA, PFNA, PFDA, PFUnDA, PFOS, PFDS, 6:2FtOH,
8:2FtOH, and 8:2FtOAcr were docked into the human, mouse,
and trout models of the ERa-LBD binding pocket. In addition,
DES (a strong ERa binder), GEN (a moderate binder), and NP
and bisphenol A (BPA) (weak binders) were included in the
docking study as reference compounds with known binding
affinities toward the ERa (this study; Matthews et al., 2000;
Olsen et al., 2005). The results of the molecular docking for all
test ligands into the LBD of hERa are shown in Figure 7,
mERa in Supplementary figure 5, and rtERa1 in Supplemen-
tary figure 6. When considered by broad groupings (strong,
moderate, weak, and very weak), the ranking by ICM score of
the docked reference compounds correlated well with the
difference in ERa-binding affinity and activity of the
compounds (Table 3). The higher score for BPA in the mouse
model is likely because of the third hydrogen bond interaction
between the compound and the side chain of residue T351
TABLE 2
IC50 and RBA Values for Competitive Ligands for the Trout Liver ER
Treatment Abbreviation IC50 (M)
a RBA (%)b Classificationc
Xenoestrogens
Estradiol E2 1.39 3 108 100 S
Diethylstilbestrol DES 7.59 3 109 186 S
Ethynylestradiol EE2 5.89 3 108 23.7 S
Genistein GEN 1.01 3 106 1.38 M
4-Nonylphenol NP 8.42 3 104 0.0017 W
Indole-3-carbinol I3C 4.81 3 103 0.0003 W
3,3#-Diindolylmethane DIM 1.76 3 103 0.0008 W
Perfluoroalkyl carboxylic acids
Perfluoropentanoic acid PFPA 2.89 3 103 0.0005 VW
Perfluorohexanoic acid PFHxA 1.22 3 103 0.0011 W
Perfluoroheptanoic acid PFHpA 1.78 3 103 0.0008 VW
Perfluorooctanoic acid PFOA 1.82 3 103 0.0008 VW
Perfluorononanoic acid PFNA 1.63 3 103 0.0009 VW
Perfluorodecanoic acid PFDA 2.34 3 104 0.0060 W
Perfluoroundecanoic acid PFUnDA 1.01 3 103 0.0014 W
Perfluorododecanoic acid PFDoDA 6.51 3 104 0.0021 W
Perfluorotridecanoic acid PFTrDA 5.22 3 104 0.0027 W
Perfluorotetradecanoic acid PFTDA L L
Perfluoroalkyl sulfonates
Perfluorooctane sulfonic
acid potassium salt
PFOS 2.01 3 104 0.0069 W
Perfluorodecane sulfonic
acid ammonium salt
PFDS 1.52 3 104 0.0092 W
Fluorotelomers
6:2 Fluorotelomer alcohol 6:2FtOH ND ND
8:2 Fluorotelomer alcohol 8:2FtOH ND ND
8:2 Fluorotelomer acrylate 8:2FtOAcr ND ND
Note. ND, no significant displacement; L, less than 50% displacement.
aIC50 is the competitor concentration that causes 50% displacement of [
3H]-E2.
bRBA values were calculated by normalizing IC50 values to that of E2 which was set at 100%.
cLetters indicate classification of RBA values into four broad groups indicating calculated affinity for trout liver ER as follows: S, strong binding (RBA > 10%);
M, moderate binding (RBA 0.1–10%); W, weak binding (RBA 0.001–0.1%); and VW, very weak binding (RBA < 0.001%).
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(Supplementary fig. 5D). The moderate binder GEN and the
weak binders BPA and NP docked into the human, mouse, and
trout ERa-LBD binding pockets with lower ICM scores than
E2 and DES because of loss of the classical triple hydrogen-
bonding pattern observed with the two strongest binders (e.g.,
hERa in Figs. 7A–E). In the binding site, GEN establishes
a triple hydrogen-bonding pattern like E2 and DES but with the
carboxyl backbone of L387/391/400 instead; this bonding
pattern is the likely cause for the improved docking score of
GEN compared with BPA and NP, which form only two
hydrogen bonds.
All PFAAs and fluorotelomer alcohol derivatives docked in
all three ERa models with similar orientations. The negative
charged oxygen of the carboxylic (PFHpA, PFOA, PFNA,
PFDA, and PFUnDA) and the sulfonic (PFOS and PFDS)
groups establishes a hydrogen bond interaction with the side
chain of R394/398/407 but not with E353/357/366 (e.g., hERa
in Figs. 7F–L). The loss of the classical hydrogen-bonding
pattern present in E2, DES, and GEN docking poses is caused
by the repulsion between the negative charge of the ligand
(carboxylic and sulfonic groups) and the side chain of
E353/357/366. Alternatively, 8:2FtOH and 6:2FtOH docked
with higher scores (with the exception of 6:2FtOH in the
mouse model) with the hydroxyl group interacting with both
side chains of R394/398/407 and E353/357/366 (e.g., hERa in
Figs. 7M and 7N). The fluorotelomer acrylate compound
8:2FtOAcr displayed a similar hydrogen-bonding pattern as the
carboxylic acids tested rather than the fluorotelomer alcohols,
likely because of the positioning of the acrylate side chain near
R394/398/407. Unlike several of the xenoestrogens studied, no
hydrogen bonding was possible with H524/528/537 for the
PFCs tested because of the orientation of the fluorinated carbon
tail near this residue. The PFAA compounds with the best
docking scores had fluorinated carbon chains of medium
length, PFDA for hERa (18.77) and PFNA for mERa and
rtERa1 (22.54 and 16.45, respectively), whereas shorter or
longer compounds have lower scores (Table 3, Fig. 6).
Space-filling models for the PFAAs showed that short carbon
chain fluorinated chemicals (e.g., PFHpA) did not adequately
fill the LBD pocket (Figs. 6B and 6F), whereas longer
fluorinated carbon chain structures (e.g., PFUnDA) were nearly
too large and required the fluorinated carbon tail to bend so that
the ligand could fit into the binding pocket (Figs. 6D and 6H).
No major differences in the pattern of xenoestrogen and PFC
docking to the LBD region of ERa were observed for the species
studied, aside from the noted different site of hydrogen bonding
for BPA in the mERa model. However, the ICM scores for
PFAA docking to the mERa model were generally somewhat
higher than those for the hERa or rtERa1 models (Table 3).
DISCUSSION
This study details the first comprehensive screen of
structurally diverse PFCs for estrogen-like activity in an
animal model that mimics human insensitivity to peroxisome
FIG. 5. Transactivation of hERa by PFAAs. HEK-293T cells were
transfected with (solid bar) or without (open bar) a human ERa-expressing
plasmid, the XTEL luciferase reporter plasmid containing a consensus ERE
sequence, and a b-galactosidase–containing plasmid for normalization of
raw luminescence data. Twenty-four hours after transfection, cells were
treated with increasing concentrations of E2 (A), PFOA (B), PFNA (C),
PFDA (D), PFUnDA (E), PFOS (F), and 8:2FtOH (G). Values are the mean
gene reporter activity expressed as fold change with respect to control
(0nM treatment) (N ¼ 3 replicate experiments). Within the ERE þ ERa
data set, *p < 0.05, **p < 0.01 as determined by one-way ANOVA with
Bonferonni post hoc tests compared with 0nM.
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proliferation, the presumed mechanism of action for PFAAs.
As has been shown previously by our laboratory for PFOA
(Tilton et al., 2008), dietary exposure to PFAAs did not elicit
a change in palmitoyl CoA oxidation or catalase activity,
indicative of a peroxisome proliferation response. Rather, eight
different PFAAs significantly increased expression of the
estrogen biomarker protein Vtg, and perfluoroalkyl carboxylic
acids were more estrogenic compared with the perfluoroalkyl
sulfonates and fluorotelomers tested.
Additionally, we provide the first evidence that PFAAs
interact directly with the ER to exert their estrogenic activity.
Results from competitive steroid-binding assays show that
multiple PFAAs effectively bind to the trout liver ER with
a structure-activity relationship similar to that observed for
in vivo Vtg induction in trout. Perfluoroalkyl carboxylic acids
ranging in size from 7 to 13 carbons were identified as
competitive binders for the rtER, with the 10-carbon compound
PFDA being the strongest binder of the chemical group.
Although not considered strong ER agonists, these PFAAs had
sufficient binding affinity for the ER that, in the absence of
endogenous estrogen (as is the case in juvenile trout), the
compounds are capable of eliciting a weak estrogen-like effect
as measured by the Vtg bioassay. The rtER is considered more
promiscuous than in other species (Matthews et al., 2000) and
has been shown to weakly bind a wide variety of
environmental xenobiotics; in this study, PFAA binding was
comparable to some of these weak estrogens, such as
nonylphenol and I3C. Interestingly, PFOS and PFDS showed
the highest affinity of all the PFCs tested for this receptor,
contradicting the fairly modest Vtg response observed for these
sulfonate compounds in vivo. This discrepancy is not likely due
to poor bioavailability of perfluoroalkyl sulfonates because
PFOS is reported to have a four-fold greater half-life in trout
than PFOA (Martin et al., 2003). Currently, it is unknown why
PFOS and PFDS are less estrogenic in vivo than would be
predicted by their RBA for the trout ER. Moreover, results of
steroid-binding assays for trout liver ER suggest that the
observed difference in Vtg response between carboxylic acids
and sulfonates is not likely the result of differing affinities for
the ER. It should be noted, as well, that the ER-binding assay
does not discriminate between the four trout ER isoforms, of
which rtERa1 and rtERb2 are highly expressed in trout liver
(Nagler et al., 2007). Finally, we observed that dietary PFOA,
PFNA, PFDA, and PFUnDA induced a marked increase in Vtg
expression in vivo, even though the binding affinity for these
compounds was classified as weak or very weak. This biomarker
assay integrates several factors that impact the biological
response to PFCs, including chemical-specific patterns of
assimilation, distribution, and elimination. The perceived discre-
pancy in the effectiveness of PFAAs in vivo versus in vitro could
be explained by the apparent accumulation of these compounds
in trout over time (14 days), which allowed for blood levels to
achieve concentrations sufficient for PFAA binding to the trout
ER and a robust Vtg response (Fig. 3).
In general, the fluorotelomers tested in this study were not
potent estrogens in vivo, save for 6:2FtOH which caused
a slight increase in Vtg expression. Similar to our observations
in trout, Liu et al. (2007) showed that PFOA, PFOS, and
6:2FtOH significantly increased Vtg expression by tilapia
hepatocytes in vitro, whereas 8:2FtOH was ineffective.
However, subsequent reports showed that aqueous exposure
to 6:2FtOH or 8:2FtOH caused significant induction of Vtg in
male zebrafish, though this may be the result of changes in
steroid metabolism rather than direct action of the chemicals
at the ER (Liu et al., 2009, 2010). On the other hand,
Ishibashi et al. (2008) reported that waterborne 6:2FtOH and
8:2FtOH increased hepatic Vtg gene expression in male
medaka and that this effect was likely linked to interaction
with the medaka ERa. Interestingly, in this same study
(Ishibashi et al., 2008) as well as another report using human
breast cancer cells (Maras et al., 2006), the authors found no
evidence for ER interaction with PFAAs. Overall, these
differences suggest that the estrogenic response to PFAAs
and fluorotelomers may depend on the route of exposure or the
species studied.
This report also describes the first broad-scale dose-response
study for estrogen-like activity of PFOA and PFDA, two
PFAAs commonly detected in humans and wildlife. Overall,
the dose-response data suggest that the compounds tested are
weakly estrogenic, as fairly high diet levels were required to
induce expression of the estrogen biomarker protein Vtg.
Neither chemical caused a significant increase in Vtg
expression at blood levels for PFOA or PFDA in trout that
correspond to the levels of these compounds observed in the
general human population, about 2–7 ppb (reviewed in
Fromme et al., 2009; Kannan et al., 2004). However,
a significant estrogenic response was observed at levels that
may reflect certain human exposures, such as residents
living near a contaminated site or occupationally exposed
workers (Emmett et al., 2006). It should be noted, however,
FIG. 6. Effect of fluorinated carbon chain length on perfluoroalkyl carboxylic acid docking orientation and efficiency for human or trout ERa proteins. The
docked orientation of E2 is represented by the stick/space-filling model in the binding pocket of the receptor (A and E). Dockings of three representative
perfluoroalkyl carboxylic acids with different fluorinated carbon chain length are shown, including PFHpA (seven carbons), PFNA (nine carbons), and PFUnDA
(11 carbons), with hERa (B–D) or rtERa1 (F–H). Interacting residues of the LBDs are shown as sticks and are colored according to their hydrophobicity (inset
scale) with hydrophobic residues colored blue and hydrophilic colored red. Hydrogen bonds are represented by black dotted lines between the donor (D) and the
acceptor (A) and are defined as follows: Distance D–A: 2.8–3.2 A˚; Angle D–H–A: 140–180. Residue labels are numbered according to the indicated protein
sequences, which are available in Supplementary figure 3. The corresponding ICM docking scores are indicated for each ligand-protein pair; scores for all PFAAs
tested are available in Table 3.
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that the in vivo studies described above are short-term
(14 day) experiments that do not precisely reflect the typical
chronic exposure to these chemicals observed in humans.
Moreover, humans and wildlife have detectable blood levels of
multiple PFCs (Calafat et al., 2007), which could have additive
or synergistic toxic effects depending on the mechanism of
action. In this study, results of a simple in vivo mixture
experiment with PFOA, PFNA, PFDA, and PFUnDA suggest
that perfluoroalkyl carboxylic acids impact Vtg expression in at
least an additive manner at higher exposures.
FIG. 7. In silico model showing docking of estrogens and select PFCs into the hERa LBD. Docking of test ligands into the hERa LBD was performed using
Molsoft ICM, and the lowest ICM-scored poses for each calculated ligand-protein docking are shown. Ligands are colored by atom type (the carbon atoms in tan)
and are displayed as ball and sticks. Relevant protein residues, including E353, R394, H524, and L387, are displayed as ball and sticks and colored by atom type:
carbon atoms in gray, oxygen in red, sulfur in yellow, and fluorine in cyan. Hydrogen bonds are represented by black dotted lines between the donor (D) and the
acceptor (A) and are defined as follows: Distance D–A: 2.8–3.2 A˚; Angle D–H–A: 140–180.
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Subsequent experiments sought to expand the findings in
trout to humans using a reporter gene assay for hERa. We
determined that certain PFAAs activate hERa-induced
transcription, including the perfluoroalkyl carboxylic acids
PFOA, PFNA, and PFDA and one sulfonate compound, PFOS,
whereas 8:2FtOH was ineffective. Although our observations
for PFC activation of hERa largely match those for ER binding
and in vivo activity in trout, they follow a pattern opposite to
that observed by Ishibashi et al. (2007); results of their studies
using a yeast two-hybrid assay suggested that fluorotelomer
alcohols, but not PFOA or PFOS, interacted with hERa. The
apparent differences in observations of these two research
groups might be explained by interassay variation associated
with the cellular and molecular responses in the bioassays
employed; one may reasonably expect that our reporter gene
assay better represents the molecular context for ER activation
in human cells. The estrogen-like activity of some
fluorotelomers could be the result of metabolic production of
polyfluorinated derivatives, such as 8:2 or 7:3 fluorotelomer
acids (Nabb et al., 2007), which have chemical structures and
lengths similar to the estrogenic perfluoroalkyl carboxylic acids
identified in this study. Moreover, substantial differences in the
metabolism of fluorotelomers in human, rodent, and trout
hepatocytes have been reported (Nabb et al., 2007).
A major focus of the present study was to understand the
potential molecular interactions of PFAAs with the LBD region
of the ER, particularly because the chemical structures of
PFAAs previously identified as estrogenic have little in
common with the structure of the native hormone or other
environmental xenoestrogens. To this end, we employed an in
silico molecular docking model to investigate docking of these
putative ligands with hERa, mERa, and rtERa1. From the
results obtained and after considering the score ranking of
the reference compounds E2, DES, GEN, BPA, and NP, the
PFAAs and fluorotelomers examined were predicted to be
in vitro weak binders and ERa activators. For the three species
investigated, the overall pattern of xenoestrogen and PFC
docking to the LBD region of ERa was fairly consistent, as all
compounds docked into each model with similar orientations.
Hydrogen bonding with the R394/398/407 (human/mouse/
rainbow trout) residue was critical for all putative ligands,
whereas more the estrogen-like compounds DES and GEN
docked with the classic triple hydrogen bond pattern, with
additional hydrogen bonds predicted at residues E353/357/366
and H524/528/537. For the PFAAs examined, docking scores
for mERa were moderately more favorable than those for the
human and trout receptors. However, it is uncertain whether
this modest difference in computed affinity for mERa would
translate into greater in vivo activity for PFAAs in mice,
especially because these chemicals are reported to have quite
different pharmacokinetic properties in rodents, humans, and
trout (Kudo and Kawashima, 2003; Martin et al., 2003).
The homology model developed for rtERa1 agreed well with
a similar computational model described by Marchand-Geneste
et al. (2006), where the natural ligand E2 formed hydrogen bonds
with active site residues E366, R407, and H537. Our docking
model appropriately predicted PFAA interaction with the trout ER
and in vivo estrogen activity, as the medium-sized compounds
TABLE 3
Molecular Modeling of Ligand Interaction with Human, Mouse, and Trout ERa LBDs
ICM docking score Hydrogen-bonding interactions
Ligand hERa mERa rtERa1 HERa mERa rtERa Classificationa
E2 38.68 37.75 36.34 R394, E353, H524 R398, E357, H528 R407, E366, H537 S
DES 38.34 37.40 37.25 R394, E353, H524 R398, E357, H528 R407, E366, H537 S
GEN 30.10 32.70 31.63 R394, L387, H524 R398, L391, H528 R407, L400, H537 M
NP 23.41 24.49 23.39 R394, L387 R398, L391 R407, L400 W
BPA 18.77 27.86 17.34 E353, H524 R398, E357, T351 E366 M,W
PFHpA 6.95 9.63 8.64 R394 R398, E357 R407 VW
PFOA 11.84 17.75 11.70 R394 R398, L391 R407 VW
PFNA 13.96 22.54 16.45 R394 R398 R407 VW,W
PFDA 18.77 20.05 13.41 R394 R398 R407 VW,W
PFUnDA 11.87 17.85 12.60 R394 R398 R407 VW,W
PFOS 15.77 19.06 10.96 R394 R398 R407 VW,W
PFDS 11.52 14.79 11.12 R394 R398 R407 VW
6:2FtOH 20.48 20.46 20.30 R394, E353 R398 R407, E366 W
8:2FtOH 18.57 25.68 18.06 R394, L387 R398 R407, L400 W
8:2FtOAcr 15.60 14.50 17.06 R394 R398 R407 W
Note. ICM scores are a measure of fit within the receptor-binding pocket, taking into account continuum and discreet electrostatics, hydrophobicity, and entropy
parameters. The predicted amino acid residue locations for hydrogen bonding are indicated for each ligand-protein docking.
aLetters indicate classification of ICM docking scores into four broad groups indicating predicted affinity for ERa as follows: S, strong affinity (ICM scores >
35); M, moderate affinity (scores 25 and 35); W, weak affinity (scores 15 to 25); and VW, very weak affinity (scores > 15). Two classifications are
given when scores for different receptors fit within multiple ranges.
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PFNA and PFDA docked to the rtERa1 with the most favorable
ICM scores of the carboxylic acids examined. However, the model
was not predictive for fluorotelomer alcohols. Despite the higher
computed docking scores for all the fluorotelomers examined in
silico, none of these compounds showed activity in vitro, and only
6:2FtOH was slightly estrogenic in vivo in trout. Moreover, the
computational models presented here do not perfectly align with
prior studies predicting positive interaction of fluorotelomers, but
not PFOA or PFOS, with human or medaka ERa (Ishibashi et al.,
2007, 2008). In silico modeling is a useful tool for predicting
potential ligand-receptor interactions or, in the case of this study,
a retrospective tool used to gain insight into ligand-receptor
interaction. However, these computational models are not perfect
predictors of in vivo or in vitro interactions. Other factors, such as
metabolism, bioavailability, or other biophysical parameters,
could account for prediction errors in translating results from
computational modeling to in vivo or in vitro experimental
systems.
In this study, we investigated molecular interactions with ERa
isoforms only, primarily because of its high expression in the liver
(Flouriot et al., 1998), which is generally considered the primary
target organ for PFC toxicity. Because the LBDs for ERa and ERb
isoforms are highly similar, it is reasonable to predict that in silico
modeling with the ERb crystal structure would generate similar
docking results as described above for ERa (Supplementary fig. 7).
In conclusion, we present here the first comprehensive
evaluation of PFAAs for estrogenic activity in vivo using an
animal model that mimics human insensitivity to PPs. Multiple
estrogenic PFAAs have been identified, and a structure-activity
relationship was observed, where a fluorinated carbon chain
length of 8–10 carbons and a carboxylic acid end group were
optimal for maximal induction of plasma biomarker proteins.
Perfluoroalkyl carboxylic acids, in particular PFOA, PFNA,
PFDA, and PFUnDA, were all potent inducers of Vtg, although
at fairly high dietary exposures. Moreover, this study provides
the first evidence for direct interaction of PFAAs with the ER,
including the persistent environmental pollutants PFOA and
PFOS. As with the in vivo Vtg assay, a structure-activity
relationship between ER interaction and fluorinated carbon chain
length was evident, with medium-sized PFAAs having the
highest binding affinity and effective concentration values and
most favorable docking scores for hERa, mERa, and/or rtERa1.
Collectively, these findings support the idea that several PFAAs
could act as weak environmental xenoestrogens.
SUPPLEMENTARY DATA
Supplementary data are available online at http://www
.toxsci.oxfordjournals.org.
Supplementary materials and methods.pdf includes experi-
mental details for measurement of PFOA and PFDA in trout
blood plasma by LC-MS/MS. Supplementary tables.pdf
contains nine additional tables, including a list of PFCs
investigated in this report (Suppl. Table 1) and morphometric
data from the in vivo experiments described above (Suppl.
Tables 2 and 3). Supplementary Figures.pdf contains seven
additional figures, including activity of peroxisome prolifer-
ator-responsive enzymes in trout liver (Suppl. Fig. 1), trout ER
saturation analyses (Suppl. Fig 2), alignment of human, mouse
and fish ERs (Suppl. Figs 3 and 7), the mouse and trout ER
homology models (Suppl. Fig 4) and results of in silico
docking of PFCs into the mouse and trout ERa LBDs (Suppl.
Figs. 5 and 6).
FUNDING
National Institute of Environmental Health Sciences (P30
ES03850, T32 ES07060, P30 ES00210, R01 ES013534);
Society of Toxicology Colgate/Palmolive Grants for
Alternative Research to A.D.B.
ACKNOWLEDGMENTS
The authors wish to acknowledge the assistance of Eric
Johnson, Greg Gonnerman, and Cari Buchner at the SARL for
care of the animals used in this study. We also thank Dr
Jennifer Field for the donation of some PFCs used in these
experiments. The technical assistance of Marilyn Henderson
and Beth Siddens is also gratefully acknowledged. Parts of the
manuscript were presented at the Society of Environmental
Toxicology and Chemistry North America 28th Annual
Meeting, Milwaukee, Wisconsin, November 11–15, 2007,
and the Society of Environmental Toxicology and Chemistry
4th World Congress, Sydney, Australia, August 3–7, 2008.
REFERENCES
Abagyan, R., Totrov, M., and Kuznetsov, D. (1994). ICM—a new method for
protein modeling and design: applications to docking and structure
prediction from the distorted native conformation. J. Comput. Chem. 15,
488–506.
Abdellatif, A. G., Preat, V., Taper, H. S., and Roberfroid, M. (1991). The
modulation of rat liver carcinogenesis by perfluorooctanoic acid, a peroxi-
some proliferator. Toxicol. Appl. Pharmacol. 111, 530–537.
Benninghoff, A. D., and Williams, D. E. (2008). Identification of
a transcriptional fingerprint of estrogen exposure in rainbow trout liver.
Toxicol. Sci. 101, 65–80.
Bisson, W. H., Koch, D. C., O’Donnell, E. F., Khalil, S. M., Kerkvliet, N. I.,
Tanguay, R. L., Abagyan, R., and Kolluri, S. K. (2009). Modeling of the
aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in
virtual ligand screening to predict new AhR ligands. J. Med. Chem. 52,
5635–5641.
Blair, R. M., Fang, H., Branham, W. S., Hass, B. S., Dial, S. L., Moland, C. L.,
Tong, W., Shi, L., Perkins, R., and Sheehan, D. M. (2000). The estrogen
receptor relative binding affinities of 188 natural and xenochemicals:
structural diversity of ligands. Toxicol. Sci. 54, 138–153.
56 BENNINGHOFF ET AL.
Bosgra, S., Mennes, W., and Seinen, W. (2005). Proceedings in uncovering the
mechanism behind peroxisome proliferator-induced hepatocarcinogenesis.
Toxicology 206, 309–323.
Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T.,
Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M.
(1997). Molecular basis of agonism and antagonism in the oestrogen
receptor. Nature 389, 753–758.
Calafat, A. M., Wong, L. Y., Kuklenyik, Z., Reidy, J. A., and Needham, L. L.
(2007). Polyfluoroalkyl chemicals in the U.S. population: data from the
National Health and Nutrition Examination Survey (NHANES) 2003-2004
and comparisons with NHANES 1999-2000. Environ. Health Perspect. 115,
1596–1602.
Cardozo, T., Totrov, M., and Abagyan, R. (1995). Homology modeling by the
ICM method. Proteins 23, 403–414.
Cavalieri, E., Frenkel, K., Liehr, J. G., Rogan, E., and Roy, D. (2000).
Estrogens as endogenous genotoxic agents—DNA adducts and mutations.
J. Natl. Cancer Inst. Monogr. 27, 75–93.
De Maria, N., Manno, M., and Villa, E. (2002). Sex hormones and liver cancer.
Mol. Cell. Endocrinol. 193, 59–63.
Eliassen, A. H., and Hankinson, S. E. (2008). Endogenous hormone levels and
risk of breast, endometrial and ovarian cancers: prospective studies. Adv.
Exp. Med. Biol. 630, 148–165.
Emmett, E. A., Shofer, F. S., Zhang, H., Freeman, D., Desai, C., and
Shaw, L. M. (2006). Community exposure to perfluorooctanoate: relation-
ships between serum concentrations and exposure sources. J. Occup.
Environ. Med. 48, 759–770.
Flouriot, G., Griffin, C., Kenealy, M., Sonntag-Buck, V., and Gannon, F.
(1998). Differentially expressed messenger RNA isoforms of the human
estrogen receptor-alpha gene are generated by alternative splicing and
promoter usage. Mol. Endocrinol. 12, 1939–1954.
Fromme, H., Tittlemier, S. A., Volkel, W., Wilhelm, M., and Twardella, D.
(2009). Perfluorinated compounds—exposure assessment for the general
population in Western countries. Int. J. Hyg. Environ. Health
212, 239–270.
Guyton, K. Z., Chiu, W. A., Bateson, T. F., Jinot, J., Scott, C. S., Brown, R. C.,
and Caldwell, J. C. (2009). A reexamination of the PPAR-alpha activation
mode of action as a basis for assessing human cancer risks of environmental
contaminants. Environ. Health Perspect. 117, 1664–1672.
Hanhijarvi, H., Ylinen, M., Haaranen, T., and Nevalainen, T. (1988). In
A Proposed Species Difference in the Renal Excretion of Perfluorooctanoic
Acid in the Beagle Dog and Rat (A. C. Beynen and H. A. Solleveld, Eds.),
pp. 409–412. Martinus Nijhoff Publishers, Dordrecht, The Netherlands.
Ho, S. M. (2003). Estrogen, progesterone and epithelial ovarian cancer.
Reprod. Biol. Endocrinol. 1, 73.
Holden, P. R., and Tugwood, J. D. (1999). Peroxisome proliferator-activated
receptor alpha: role in rodent liver cancer and species differences. J. Mol.
Endocrinol. 22, 1–8.
Houde, M., Martin, J. W., Letcher, R. J., Solomon, K. R., and Muir, D. C.
(2006). Biological monitoring of polyfluoroalkyl substances: a review.
Environ. Sci. Technol. 40, 3463–3473.
Ishibashi, H., Ishida, H., Matsuoka, M., Tominaga, N., and Arizono, K. (2007).
Estrogenic effects of fluorotelomer alcohols for human estrogen
receptor isoforms alpha and beta in vitro. Biol. Pharm. Bull. 30,
1358–1359.
Ishibashi, H., Yamauchi, R., Matsuoka, M., Kim, J. W., Hirano, M.,
Yamaguchi, A., Tominaga, N., and Arizono, K. (2008). Fluorotelomer
alcohols induce hepatic vitellogenin through activation of the estrogen
receptor in male medaka (Oryzias latipes). Chemosphere 71, 1853–1859.
Ito, Y., Yamanoshita, O., Asaeda, N., Tagawa, Y., Lee, C. H., Aoyama, T.,
Ichihara, G., Furuhashi, K., Kamijima, M., Gonzalez, F. J., et al. (2007).
Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxi-
some proliferator-activated receptor alpha-independent pathway. J. Occup.
Health 49, 172–182.
Kannan, K., Corsolini, S., Falandysz, J., Fillmann, G., Kumar, K. S.,
Loganathan, B. G., Mohd, M. A., Olivero, J., Van Wouwe, N.,
Yang, J. H., et al. (2004). Perfluorooctanesulfonate and related fluorochem-
icals in human blood from several countries. Environ. Sci. Technol. 38,
4489–4495.
Kannan, K., Corsolini, S., Falandysz, J., Oehme, G., Focardi, S., and
Giesy, J. P. (2002). Perfluorooctanesulfonate and related fluorinated
hydrocarbons in marine mammals, fishes, and birds from coasts of the
Baltic and the Mediterranean Seas. Environ. Sci. Technol. 36,
3210–3216.
Kennedy, G. L., Jr., Butenhoff, J. L., Olsen, G. W., O’Connor, J. C.,
Seacat, A. M., Perkins, R. G., Biegel, L. B., Murphy, S. R., and Farrar, D. G.
(2004). The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 34,
351–384.
Kolluri, S. K., Bruey-Sedano, N., Cao, X., Lin, B., Lin, F., Han, Y. H.,
Dawson, M. I., and Zhang, X. K. (2003). Mitogenic effect of orphan receptor
TR3 and its regulation by MEKK1 in lung cancer cells. Mol. Cell. Biol. 23,
8651–8667.
Kudo, N., and Kawashima, Y. (2003). Toxicity and toxicokinetics
of perfluorooctanoic acid in humans and animals. J. Toxicol. Sci. 28,
49–57.
Lai, D. Y. (2004). Rodent carcinogenicity of peroxisome proliferators and
issues on human relevance. J. Environ. Sci. Health C 22, 37–55.
Liu, C., Deng, J., Yu, L., Ramesh, M., and Zhou, B. (2010). Endocrine
disruption and reproductive impairment in zebrafish by exposure to 8:2
fluorotelomer alcohol. Aquat. Toxicol. 96, 70–76.
Liu, C., Du, Y., and Zhou, B. (2007). Evaluation of estrogenic activities and
mechanism of action of perfluorinated chemicals determined by vitellogenin
induction in primary cultured tilapia hepatocytes. Aquat. Toxicol. 85,
267–277.
Liu, C., Yu, L., Deng, J., Lam, P. K., Wu, R. S., and Zhou, B. (2009).
Waterborne exposure to fluorotelomer alcohol 6:2 FTOH alters plasma sex
hormone and gene transcription in the hypothalamic-pituitary-gonadal
(HPG) axis of zebrafish. Aquat. Toxicol. 93, 131–137.
Maras, M., Vanparys, C., Muylle, F., Robbens, J., Berger, U., Barber, J. L.,
Blust, R., and De Coen, W. (2006). Estrogen-like properties of fluorotelomer
alcohols as revealed by mcf-7 breast cancer cell proliferation. Environ.
Health Perspect. 114, 100–105.
Marchand-Geneste, N., Cazaunau, M., Carpy, A. J., Laguerre, M.,
Porcher, J. M., and Devillers, J. (2006). Homology model of the rainbow
trout estrogen receptor (rtERalpha) and docking of endocrine disrupting
chemicals (EDCs). SAR QSAR Environ. Res. 17, 93–105.
Martin, J. W., Mabury, S. A., and O’Brien, P. J. (2005). Metabolic products
and pathways of fluorotelomer alcohols in isolated rat hepatocytes. Chem.
Biol. Interact. 155, 165–180.
Martin, J. W., Mabury, S. A., Solomon, K. R., and Muir, D. C. (2003). Dietary
accumulation of perfluorinated acids in juvenile rainbow trout (Oncorhyn-
chus mykiss). Environ. Toxicol. Chem. 22, 189–195.
Matthews, J., Celius, T., Halgren, R., and Zacharewski, T. (2000). Differential
estrogen receptor binding of estrogenic substances: a species comparison.
J. Steroid Biochem. Mol. Biol. 74, 223–234.
Mitchell, A. M., Lhuguenot, J. C., Bridges, J. W., and Elcombe, C. R. (1985).
Identification of the proximate peroxisome proliferator(s) derived
from di(2-ethylhexyl) phthalate. Toxicol. Appl. Pharmacol.
80, 23–32.
Nabb, D. L., Szostek, B., Himmelstein, M. W., Mawn, M. P., Gargas, M. L.,
Sweeney, L. M., Stadler, J. C., Buck, R. C., and Fasano, W. J. (2007).
In vitro metabolism of 8-2 fluorotelomer alcohol: interspecies comparisons
and metabolic pathway refinement. Toxicol. Sci. 100, 333–344.
ESTROGEN-LIKE ACTIVITY OF PFAAS 57
Nagler, J. J., Cavileer, T., Sullivan, J., Cyr, D. G., and Rexroad, C., III. (2007).
The complete nuclear estrogen receptor family in the rainbow trout:
discovery of the novel ERalpha2 and both ERbeta isoforms. Gene 392,
164–173.
Nu´n˜ez, O., Hendricks, J. D., Arbogast, D. N., Fong, A. T., Lee, B. C., and
Bailey, G. S. (1989). Promotion of aflatoxin B1 hepatocarcinogenesis in
rainbow trout by 17b-estradiol. Aquat. Toxicol. 15, 289–302.
Olsen, C. M., Meussen-Elholm, E. T., Hongslo, J. K., Stenersen, J., and
Tollefsen, K. E. (2005). Estrogenic effects of environmental chemicals: an
interspecies comparison. Comp. Biochem. Physiol. C Toxicol. Pharmacol.
141, 267–274.
Olsen, G. W., Burris, J. M., Ehresman, D. J., Froehlich, J. W., Seacat, A. M.,
Butenhoff, J. L., and Zobel, L. R. (2007). Half-life of serum elimination of
perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate
in retired fluorochemical production workers. Environ. Health Perspect. 115,
1298–1305.
Orner, G. A., Mathews, C., Hendricks, J. D., Carpenter, H. M., Bailey, G. S.,
and Williams, D. E. (1995). Dehydroepiandrosterone is a complete
hepatocarcinogen and potent tumor promoter in the absence of peroxisome
proliferation in rainbow trout. Carcinogenesis 16, 2893–2898.
Palmer, C. N., Hsu, M. H., Griffin, K. J., Raucy, J. L., and Johnson, E. F.
(1998). Peroxisome proliferator activated receptor-alpha expression in
human liver. Mol. Pharmacol. 53, 14–22.
Persson, I. (2000). Estrogens in the causation of breast, endometrial and ovarian
cancers—evidence and hypotheses from epidemiological findings. J. Steroid
Biochem. Mol. Biol. 74, 357–364.
Shilling, A. D., and Williams, D. E. (2000). Determining relative estrogenicity
by quantifying vitellogenin induction in rainbow trout liver slices. Toxicol.
Appl. Pharmacol. 164, 330–335.
Sivanesan, D., Rajnarayanan, R. V., Doherty, J., and Pattabiraman, N. (2005).
In-silico screening using flexible ligand binding pockets: a molecular
dynamics-based approach. J. Comput. Aided Mol. Des. 19, 213–228.
Tilton, S. C., Orner, G. A., Benninghoff, A. D., Carpenter, H. M., Hendricks, J. D.,
Pereira, C. B., and Williams, D. E. (2008). Genomic profiling reveals an alternate
mechanism for hepatic tumor promotion by perfluorooctanoic acid in rainbow
trout. Environ. Health Perspect. 116, 1047–1055.
Totrov, M., and Abagyan, R. (1997). Flexible protein-ligand docking by global
energy optimization in internal coordinates. Proteins Suppl 1, 215–220.
Totrov, M., and Abagyan, R. (2001). In Protein-Ligand Docking as an Energy
Optimization Problem (R. B. Raffa, Ed.), pp. 603–624. John Wiley & Sons,
New York, NY.
Villa, E. (2008). Role of estrogen in liver cancer. Womens Health (Lond. Engl.)
4, 41–50.
Wei, Y., Dai, J., Liu, M., Wang, J., Xu, M., Zha, J., and Wang, Z. (2007).
Estrogen-like properties of perfluorooctanoic acid as revealed by expressing
hepatic estrogen-responsive genes in rare minnows (Gobiocypris rarus).
Environ. Toxicol. Chem. 26, 2440–2447.
Yager, J. D., Zurlo, J., and Ni, N. (1991). Sex hormones and tumor promotion
in liver. Proc. Soc. Exp. Biol. Med. 198, 667–674.
Yeh, S. H., and Chen, P. J. (2010). Gender disparity of hepatocellu-
lar carcinoma: the roles of sex hormones. Oncology 78(Suppl. 1),
172–179.
58 BENNINGHOFF ET AL.
